Cytochrome P450 (CYP)

Overview

Cytochrome P450 (CYP) refers to a large superfamily of heme-containing enzymes that catalyze oxidative metabolism of a wide range of endogenous compounds and xenobiotics. In humans, CYP enzymes are central to drug biotransformation, steroid and lipid metabolism, and the clearance or activation of many therapeutic agents. Because of this broad substrate specificity, cytochrome P450 proteins are among the most important determinants of pharmacokinetics, drug–drug interactions, and interindividual variability in drug response.

Clinically, specific CYP isoforms such as CYP3A4, CYP2C9, CYP2D6, CYP1A2, and CYP11A1 are frequently studied as drug-metabolizing or biosynthetic targets. Their activity can be altered by genetic polymorphism, enzyme inhibition, induction, or tissue-specific expression changes. As a result, cytochrome P450 enzymes are routinely evaluated in drug development, toxicity screening, and precision medicine, particularly in relation to compounds such as midazolam, omeprazole, tolbutamide, fluconazole, clopidogrel, and oral contraceptives.

Recent Publications Summary

Recent studies continued to highlight the central role of cytochrome P450 enzymes in drug metabolism, pharmacokinetic variability, and drug–drug interaction risk. In siponimod, clinical interaction data and updated physiologically based pharmacokinetic modeling showed that the CYP3A4 inhibitor clarithromycin produced only minimal changes in exposure in participants with the CYP2C9*1/3 genotype, supporting the conclusion that there was no clinically relevant interaction; the revised model estimated a CYP3A4 fraction metabolized of 6.4% in the CYP2C91/*1 genotype and predicted no clinically relevant interaction with moderate or strong CYP3A4 inhibitors across CYP2C9 genotypes 42364973Jun. A related review of humanized liver chimeric mice emphasized that these models can reproduce human CYP3A- and CYP2C9-mediated drug–drug interactions and help estimate fraction metabolized values, although validation data remain limited 41780327Mar.

CYP enzymes were also examined in the context of antiplatelet therapy and pharmacogenetics. In patients with recurrent ischemic stroke receiving clopidogrel monotherapy, combined genotyping of ABCB1, CYP2C19, CYP2C9, and other enzymes suggested that clopidogrel resistance was most strongly associated with ABCB1 phenotype distribution overall, while CYP2C19 intermediate and poor metabolism were associated with resistance in patients with normal ABCB1 efflux activity; among patients with normal CYP2C19 metabolism, CYP2C9 intermediate and poor metabolism were also significantly associated 42303966Jun. Consistent with the importance of CYP-mediated activation of clopidogrel, an intravenous micellar formulation was developed to promote rapid hepatic exposure and CYP450-mediated bioactivation for emergency antiplatelet therapy, with proteomic profiling indicating selective recruitment of liver-affinity apolipoproteins and reduced adsorption of inflammatory and opsonization proteins 41692042Feb.

Methodological advances and broader toxicology applications also featured prominently. DeepCYP, a deep-learning web server, was introduced for holistic prediction of CYP450 metabolism across nine major isoforms, integrating pathway, site, and product prediction in a unified pipeline and outperforming established tools in benchmark testing 42152517May. In toxicology, zearalenone-14-glucoside was reported to form a self-assembled supramolecular gel that slowly released zearalenone, and proteomic and toxicological analyses suggested that its stronger tissue toxicity relative to zearalenone was achieved through depletion of cytochrome P450 42009287Apr. In another in silico study of garlic-derived organosulfur compounds in breast cancer, only Z-ajoene was predicted to inhibit CYP2C9, raising the possibility of drug–drug interactions alongside the compounds’ proposed multi-target anticancer activity 42090396May.

What Changes, What Holds

1. CYP3A4 interaction risk remains modest in siponimod, but the fraction-metabolized estimate is now more tightly bounded
REINFORCES Clarithromycin did not produce a clinically relevant exposure change, so the established view of cytochrome P450 enzymes as major determinants of drug–drug interaction risk is strengthened rather than revised 42364973Jun. The added modeling mainly sharpens how much CYP3A4 contributes in this setting and suggests that even moderate or strong CYP3A4 inhibition may not meaningfully alter siponimod exposure across CYP2C9 genotypes. The humanized-liver mouse work supports the same general use of CYP models, though validation remains incomplete 41780327Mar.

2. CYP2C19 and CYP2C9 status can shape clopidogrel resistance alongside transporter effects
REINFORCES The new genotyping data do not overturn the established role of CYP enzymes in clopidogrel activation; they refine it by showing that resistance is not explained by CYP variation alone and may depend on ABCB1 context 42303966Jun. That makes the pharmacogenetic picture more conditional than a single-enzyme model, but it still fits the baseline account that CYP-mediated bioactivation is central to clopidogrel response. The formulation work likewise extends an established use case by trying to improve hepatic delivery for CYP450-dependent activation 41692042Feb.

3. CYP prediction is becoming a unified computational task rather than a single-site classification problem
METHOD DeepCYP changes how CYP450 metabolism is studied by combining pathway, site, and product prediction across multiple isoforms in one pipeline 42152517May. That is a methodological advance, not a change to what CYP enzymes are known to do. The toxicology and in silico screening findings add examples of CYP involvement in tissue toxicity and interaction risk, but they do not alter the baseline understanding of CYPs as broad metabolic determinants 42009287Apr42090396May.

Overview update candidates: none.